Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection
Erin D. Michos, George L. Bakris, Helena W. Rodbard, et al.
American Journal of Preventive Cardiology (2023) Vol. 14, pp. 100502-100502
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2058-2066
Open Access | Times Cited: 58
The impact of population ageing on the burden of chronic kidney disease
Nicholas C. Chesnaye, Alberto Ortíz, Carmine Zoccali, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 9, pp. 569-585
Closed Access | Times Cited: 34
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Sankar D. Navaneethan, Nisha Bansal, Kerri L. Cavanaugh, et al.
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 17
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Ellen M. Apperloo, José Luis Górriz, María José Soler, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 16
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Rosa F Drummond, Karl Seif, E. Albert Reece
American Journal of Obstetrics and Gynecology (2024) Vol. 232, Iss. 1, pp. 17-25
Closed Access | Times Cited: 15
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Alessio Mazzieri, Francesca Porcellati, Francesca Timio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3969-3969
Open Access | Times Cited: 13
The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study
Mark Ayoub, Carol Faris, Tajana Juranovic, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1625-1625
Open Access | Times Cited: 12
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Modern Management of Cardiometabolic Continuum: From Overweight/Obesity to Prediabetes/Type 2 Diabetes Mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group
Andrej Janež, Emir Muzurović, Paweł Bogdański, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 9, pp. 1865-1892
Open Access | Times Cited: 11
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression
Michael W. Holliday, Livia Frost, Sankar D. Navaneethan
Current Opinion in Nephrology & Hypertension (2024) Vol. 33, Iss. 3, pp. 331-336
Closed Access | Times Cited: 9
Skeletal Muscle Injury in Chronic Kidney Disease—From Histologic Changes to Molecular Mechanisms and to Novel Therapies
Kylie Heitman, Matthew S. Alexander, Christian Faul
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5117-5117
Open Access | Times Cited: 8
Cardiovascular and Kidney Outcomes of Glucagon-Like Peptide 1 Receptor Agonist Therapy in Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Nicole Felix, Mateus de Miranda Gauza, Vinicius Bittar, et al.
Cardiorenal Medicine (2025) Vol. 15, Iss. 1, pp. 98-107
Open Access | Times Cited: 1
Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
Aaron A. King, Xi Tan, Neil Dhopeshwarkar, et al.
American Journal of Preventive Cardiology (2025) Vol. 21, pp. 100922-100922
Open Access | Times Cited: 1
Albuminuria in Cardiovascular, Kidney, and Metabolic Disorders: A State-of-the-Art Review
Sophie E. Claudel, Ashish Verma
Circulation (2025) Vol. 151, Iss. 10, pp. 716-732
Closed Access | Times Cited: 1
Management of chronic kidney disease: The current novel and forgotten therapies
Ákos Pethő, Mihály Tapolyai, Éva Csongrádi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100354-100354
Open Access | Times Cited: 7
Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease
Merita Rroji, Goce Spasovski
Biomedicines (2024) Vol. 12, Iss. 3, pp. 657-657
Open Access | Times Cited: 5
The early diagnosis and treatment of chronic renal insufficiency
Kai-Michael Hahn, Frank Strutz
Deutsches Ärzteblatt international (2024)
Closed Access | Times Cited: 5
Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients with Established Kidney Disease
Ali Aminian, Hamlet Gasoyan, Alexander Zajichek, et al.
Annals of Surgery (2024)
Closed Access | Times Cited: 5
Glucagon-like peptide-1 agonists in cardiovascular diseases, a bibliometric analysis from inception to 2023
Abinash Mahapatro, Ali Bozorgi, Sri Usha Jeevani Obulareddy, et al.
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 11, pp. 6602-6618
Open Access | Times Cited: 5
Advancements in the Research of Non-Immunosuppressive Therapies for Chronic Kidney Disease
欣菲 王
Advances in Clinical Medicine (2025) Vol. 15, Iss. 01, pp. 2193-2202
Closed Access
The impact of weight loss on renal function in individuals with obesity and type 2 diabetes: a comprehensive review
Xuemei Gong, Xiaoxi Zeng, Ping Fu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 4
Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future
Ying Jie Chee, Rinkoo Dalan
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1386-1386
Open Access | Times Cited: 4
The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function
Kanella Kantreva, Paraskevi Κatsaounou, Katerina Saltiki, et al.
Endocrine (2024)
Closed Access | Times Cited: 4
Glucagon‐Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26‐Week Prospective Observational Real‐Life Study
Alfredo Vozza, Sara Volpe, Carlo Custodero, et al.
Journal of Diabetes Research (2025) Vol. 2025, Iss. 1
Open Access
Page 1 - Next Page

Scroll to top